By Lighthouse Instruments
Published in: Pharmaceutical online
Published on: November 21, 2022
The revised EU Annex 1 contains new requirements for ensuring the container closure integrity (CCI) of sterile pharmaceutical products, causing pharmaceutical companies to reassess their CCI policies for compliance.
Learn in detail how the new requirements of the revised EU Annex 1 may impact your strategy for ensuring CCI of sterile pharmaceutical products. Gain an understanding of the advantages and disadvantages of CCI testing methods and why a science-based holistic approach to ensure good CCI is important. Explore how cold chain storage and transport can impact the CCI of sterile pharmaceutical products.